Calculating utility: preclinical evidence for cost–benefit analysis by mesolimbic dopamine

Author： Phillips Paul   Walton Mark   Jhou Thomas  

Publisher： Springer Publishing Company

ISSN： 0033-3158

Source： Psychopharmacology, Vol.191, Iss.3, 2007-04, pp. : 483-495

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Cost-benefit or cost-utility analysis?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 315, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Cost-Benefit Analysis of Amtolmetin-Guacil

By Belisari A.   Mantovani L.G.  

Clinical Drug Investigation, Vol. 21, Iss. 1, 2001-01 ,pp. : 47-58

Adis International

Access to resources Recommend Favorite

An introduction to cost-effectiveness and cost–benefit analysis of pharmacogenomics

By Phillips Kathryn A   Veenstra David   Bebber Stephanie Van   Sakowski Julie  

Pharmacogenomics, Vol. 4, Iss. 3, 2003-05 ,pp. : 231-239

Future Medicine

Access to resources Recommend Favorite

A cost–benefit analysis of chemotherapy for gastric cancer

By Galizia Eva   Berardi Rossana   Scartozzi Mario   Cascinu Stefano  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 10, 2004-10 ,pp. : 2109-2114

Informa Healthcare

Access to resources Recommend Favorite

Measuring Health Preferences for Use in Cost-Utility and Cost-Benefit Analyses of Interventions in Children: Theoretical and Methodological Considerations

By Prosser Lisa A.  

PharmacoEconomics, Vol. 25, Iss. 9, 2007-01 ,pp. : 713-726

Adis International

Access to resources Recommend Favorite